Agilent Technologies

509 articles with Agilent Technologies

• Clinical Utility of ALK Fusion Detection by Liquid Biopsy

  7/27/2021

  Agilent Technologies Inc. (NYSE: A) today announced the publication of a paper in the journal Lung Cancer, titled "Clinical Utility of Next-Generation Sequencing-Based ctDNA Testing for Common and Novel ALK Fusions".

• Agilent Technologies Celebrates More than 20 Years of Sustainable Progress

  7/22/2021

  Agilent Technologies, Inc. (NYSE: A) today issued its 21 st annual Corporate Social Responsibility (CSR) report .

• Agilent to Webcast Third-Quarter Fiscal Year 2021 Financial Results Presentation

  7/21/2021

  Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, August 17.

• Thomas Scientific Lands Agilent as Distribution Partner

  7/20/2021

  The nation's largest pure-play distributor of scientific products continues their strong growth through agreement with industry leader

• Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

  7/20/2021

  Agilent Technologies Inc. (NYSE: A) today announced that the company’s PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

• Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds

  7/20/2021

  Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS) in drinking and surface water using liquid chromatography and mass spectrometry.

• DELIC Labs Announces Partnership Agreement with Agilent Technologies

  6/30/2021

  Delic Corp today announced that its subsidiary, DELIC Labs , has entered into a partnership agreement with Agilent, a global leader in life sciences, diagnostics, and applied chemical markets.

• Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition

  6/28/2021

  Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute .

• Agilent Completes the InfinityLab Bio LC Portfolio

  6/22/2021

  Agilent Technologies Inc. announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry.

• Agilent Presents Thought Leader Award to Dr. Stéphane Bayen

  6/14/2021

  Agilent Technologies Inc. (NYSE: A) today announced that Stéphane Bayen has received an Agilent Thought Leader Award.

• Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer

  6/4/2021

  Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung

• Agilent Presents Thought Leader Award to Professor Chris Elliott

  6/1/2021

  Agilent Technologies Inc. (NYSE: A) today announced that Chris Elliott has received an Agilent Thought Leader Award. Dr. Elliott is Professor of Food Safety in the School of Biological Sciences and founder of the Institute for Global Food Security (IGFS) at Queen’s University Belfast in Northern Ireland.

• Agilent Reports Second-Quarter Fiscal Year 2021 Financial Results

  5/25/2021

  Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.525 billion for the second quarter ended April 30, 2021, an increase of 23% compared to the second quarter of 2020 and up 19% on a core(1) basis.

• Agilent to Present at Jefferies Virtual Healthcare Conference - May 20, 2021

  5/20/2021

  Agilent Technologies Inc. announced the company will participate in the Jefferies Virtual Healthcare Conference on June 1.

• Agilent LC/MS Instruments Receive ACT Labels from My Green Lab

  4/22/2021

  Agilent Technologies Inc. (NYSE: A) announced today that both the InfinityLab LC/MSD iQ and the Ultivo Triple Quadrupole LC/MS systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.

• Agilent Named One of the Best U.S. Companies for Diversity for Third Straight Year

  4/20/2021

  Agilent Technologies (NYSE: A) today was named one of the top U.S. companies for diversity, marking the third straight year it has been recognized for its commitment to fostering a diverse and inclusive workplace.

• Agilent Completes Acquisition of Resolution Bioscience, Expands Role in Fast-growing NGS Market for Precision Oncology

  4/15/2021

  Agilent Technologies, Inc. (NYSE: A) today announced it has completed the acquisition of Resolution Bioscience, a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions.

• Agilent Awards Octagon Therapeutics with a Golden Ticket at LabCentral

  3/30/2021

  Agilent Technologies Inc. (NYSE: A) announces that Octagon Therapeutics has been awarded an Agilent Golden Ticket at LabCentral

• 

  Agilent Adds Liquid Biopsy Assay to Diagnostic Tool Bag with $550 Million Buy

  3/2/2021

  If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.

• InterVenn Enters into Collaboration with Agilent Technologies on Clinical Glycoproteomic Analysis

  10/20/2020

  InterVenn has announced a collaboration with Agilent Technologies, a leading provider of bio-analytical and scientific instrumentation.